Gansukh Choijilsuren

Gansukh Choijilsuren

Auto-generated profile, based on publicly available information

Gansukh Choijilsuren

Department of Immunology, School of Biomedicine, Mongolian National University of Medical Sciences, Ulaanbaatar 14210, Mongolia

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 June 2025 in Science Translational Medicine
Verified
Journal Article
Closed access
HZHuihui Zhang
Huihui Zhang
RZRunbo Zhong
Runbo Zhong
WWWanting Wang
Wanting Wang
YHYue Huang
Yue Huang
FLFanlin Li
Fanlin Li
XYXuanming Yang
Xuanming Yang
Although chimeric antigen receptor (CAR)–modified T cells have shown great success in treating B cell malignancies, they have demonstrated only limited efficacy against solid tumors. Here, we designed a CAR by integrating an antigen-independent OX40 that showed superior antitumor efficacy against multiple solid tumors. We unexpectedly found, through a CRISPR-Cas9–based whole-genome screen, that heparan sulfate is a ligand for OX40. We found that heparan sulfate can directly bind OX40 at the biochemical and cellular levels and that the interaction of heparan sulfate and OX40 activated the AKT, MAPK, and NF-κB signaling pathways. Functionally, the heparan sulfate–OX40 interaction enhanced cell adhesion and CAR T cell functional binding avidity to tumor cells. In vivo, OX40-expressing CAR T cells exhibited increased solid tumor infiltration and persistence dependent on the OX40–heparan sulfate interaction. Our findings provide insights into a glycan-costimulation interaction that is capable of regulating T cell immunity and has potential application in CAR T cell optimization.

8 December 2023 in PLOS ONE
Verified
Journal Article
Open access
PDF file
BBBurenjargal Batmunkh
Burenjargal Batmunkh
DODashpagma Otgonbayar
Dashpagma Otgonbayar
SSShatar Shaarii
Shatar Shaarii
NKNansalmaa Nansaa Khaidav
Nansalmaa Nansaa Khaidav
OSOyu-Erdene Shagdarsuren
Oyu-Erdene Shagdarsuren
TSTsogtsaikhan Sandag
Tsogtsaikhan Sandag
The SARS-CoV-2 vaccination campaign began in February 2021 and achieved a high rate of 62.7% of the total population fully vaccinated by August 16, 2021, in Mongolia. We aimed to assess the initial protective antibody production after two doses of a variety of types of SARS-CoV-2 vaccines in the Mongolian pre-vaccine antibody-naïve adult population. This prospective study was conducted from March-April to July-August of 2021. All participants received one of the four government-proposed COVID-19 vaccines including Pfizer/BioNTech (BNT162b2), AstraZeneca (ChAdOx1-S), Sinopharm (BBIBP-CorV), and Sputnik V (Gam-COVID-Vac). Before receiving the first shot, anti-SARS-CoV-2 S-RBD human IgG titers were measured in all participants (n = 1833), and titers were measured 21–28 days after the second shot in a subset of participants (n = 831). We found an overall average protective antibody response of 84.8% (705 of 831 vaccinated) in 21–28 days after two doses of the four types of COVID-19 vaccines. Seropositivity and titer of protective antibodies produced after two shots of vaccine were associated with the vaccine types, age, and residence of vaccinees. Seropositivity rate varied significantly between vaccine types, 80.0% (28 of 35) for AstraZeneca ChAdOx1-S; 97.0% (193 of 199) for Pfizer BNT162b2; 80.7% (474 of 587) for Sinopharm BBIBP-CorV, and 100.0% (10 of 10) for Sputnik V Gam-COVID-Vac, respectively. Immunocompromised vaccinees with increased risk for developing severe COVID-19 disease had received the Pfizer vaccine and demonstrated a high rate of seropositivity. A high geometric mean titer (GMT) was found in vaccinees who received BNT162b2, while vaccinees who received ChAdOx1-S, Sputnik V, and BBIBP-CorV showed a lower GMT. In summary, we observed first stages of the immunization campaign against COVID-19 in Mongolia have been completed successfully, with a high immunogenicity level achieved among the population with an increased risk for developing severe illness.

17 September 2025
Verified
Book Chapter
Open access
PDF file
SUSuvd-Erdene Uurdmunkh
Suvd-Erdene Uurdmunkh
GCGansukh Choijilsuren
Gansukh Choijilsuren
UTUlziikhuu Tumurkhuyag
Ulziikhuu Tumurkhuyag
ABAriunzaya Bat-Erdene
Ariunzaya Bat-Erdene
UBUlziisaikhan Bat-Itgel
Ulziisaikhan Bat-Itgel
TSTsogtsaikhan Sandag
Tsogtsaikhan Sandag
CAR-T cell therapy is a cutting-edge form of immunotherapy that involves extracting T cells from a patient, genetically modifying them into CART cells, and then reinfusing them to the target and to eliminate cancer cells. Lentiviruses are commonly used in this process to deliver the chimeric antigen receptor (CAR) gene into T cells, enabling them to recognize and attack cancer cells. Recombinant lentiviral vectors are especially advantageous because they can transduce both dividing and non-dividing cells, are generally considered safe, and provide long-term transgene expression. This is due to the integration of the viral genome known as the provirus into the host cell’s DNA, allowing it to be passed on to daughter cells. These properties are particularly important for CAR-T cell therapy, where stable and sustained expression of the CAR is essential. Lentiviral vectors are often used to deliver protein-encoding cDNAs, such as CAR constructs or reporter genes, as well as noncoding sequences for RNA interference or genome editing, including shRNA or gRNA. This study aimed to construct and validate lentiviral vectors for use in CAR-T cell therapy. Four essential plasmids—pMDLg/pRRE, pRSV-Rev, pCMV-VSV-G, and a CAR-encoding plasmid—were successfully amplified using competent cells. The plasmids were then purified, quantified, and transfected into HEK293T cells using PEI STAR. Lentiviral particles were harvested post-transfection and confirmed by RT-qPCR. In HEK293T cells, transduction efficiency reached 24.5%, while transfection efficiency was measured at 80%, as determined by fluorescence microscopy and flow cytometry. These results confirm the successful construction of functional lentiviral vectors suitable for downstream CAR-T cell applications. This establishes a foundational platform for CAR-T cell applications development in Mongolia.